Inorganic arsenic is considered a high-priority hazard, particularly because of its potential to be a human carcinogen. In exposed human populations, arsenic is associated with tumors of the lung, skin, bladder, and liver. While it is known to be a human carcinogen, carcinogenesis in laboratory animals by this metalloid has never been convincingly demonstrated. Therefore, no animal models exist for studying molecular mechanisms of arsenic carcinogenesis. The apparent human sensitivity, combined with our incomplete understanding about mechanisms of carcinogenic action, create important public health concerns and challenges in risk assessment, which could be met by understanding the role of metabolism in arsenic toxicity and carcinogenesis. This symposium summary covers three critical major areas involving arsenic metabolism: its biodiversity, the role of arsenic metabolism in molecular mechanisms of carcinogenesis, and the impact of arsenic metabolism on human risk assessment. In mammals, arsenic is metabolized to mono-and dimethylated species by methyltransferase enzymes in reactions that require S-adenosyl-methionine (SAM) as the methyl donating cofactor. A remarkable species diversity in arsenic methyltransferase activity may account for the wide variability in sensitivity of humans and animals to arsenic toxicity. Arsenic interferes with DNA methyltransferases, resulting in inactivation of tumor suppressor genes through DNA hypermethylation. Other studies suggest that arsenic-induced malignant transformation is linked to DNA hypomethylation subsequent to depletion of SAM, which results in aberrant gene activation, including oncogenes. Urinary profiles of arsenic metabolites may be a valuable tool for assessing human susceptibility to arsenic carcinogenesis. While controversial, the idea that unique arsenic metabolic properties may explain the apparent non-linear threshold response for arsenic carcinogenesis in humans. In order to address these outstanding issues, further efforts are required to identify an appropriate animal model to elucidate carcinogenic mechanisms of action, and to define dose-response relationships.
Inorganic arsenic species are widely found throughout the environment. Arsenic has been ranked highest in priority on a list of top 20 hazardous substances by the ATSDR and the USEPA (ATSDR, 1997), in part because it has been classified as a known human carcinogen (IARC, 1987) . In fact, at the end of the last century arsenic was recognized as one of the first human carcinogens. Unfortunately, there continues to be significant worldwide arsenic exposure to humans from both naturally occurring and anthropogenic sources (Fig. 1) . Oral exposures to arsenic occur through contamination of food, drinking water, and soil. Ambient levels of arsenic in drinking water can be high in some locales. Inhalation of arsenic compounds can occur in occupations involved with agriculture, mining/smelting operations, and microelectronics, and occurs secondarily, to the general public, from burning of fossil fuels. In exposed human populations, arsenic has been primarily associated with tumors of the skin and lungs, but also can be associated with tumors of the bladder, kidney, and liver. Although arsenic is clearly a human carcinogen, its carcinogenicity remains an enigma. In fact, arsenic is the only agent that the International Agency for Research on Cancer has determined to be a definitive human carcinogen in the face of "inadequate" evidence of carcinogenic potential in animals (IARC, 1980 (IARC, , 1987 . Animal carcinogenicity data for arsenic is considered either negative or equivocal (IARC, 1980 (IARC, , 1987 , which precludes its classification as an animal carcinogen.
Thus, the unsettling possibility exists that humans may be more sensitive than experimental animals to cancers induced by this ubiquitous metalloid.
Arsenic has a long history of use as a medicinal, and although many of these applications have been replaced with more appropriate therapeutics, the use of arsenic compounds in cancer chemotherapy directed against acute promyelocytic leukemia is being actively investigated (Chen et al., 1996) . The fact that arsenic can have both carcinogenic and anticarcinogenic effects may complicate the definition of the mechanisms involved.
The precise cellular mechanism by which arsenic induces cancer is unknown, and no unified hypothesis has been recognized, in large part due to the lack of validated, reproducible animal cancer models. Animal bioassays are considered either flawed or incomplete for establishing carcinogenicity of arsenic in rodents (IARC, 1980 (IARC, , 1987 . To date, a variety of possible modes of action has been proposed for arsenic carcinogenesis ( Fig. 2) , modes which are not necessarily mutually exclusive, and some may be operating concurrently or sequentially. For example, arsenic-initiated oxidative stress can be associated with chromosomal abnormalities, while arsenicinduced altered DNA repair could affect cell proliferation or accumulation. Neither arsenite or arsenate has been shown to interact directly with DNA as point mutagens, nor are these compounds DNA-reactive electrophiles. Yet, by an unknown mechanism, inorganic arsenic produces chromosomal-type damage. In addition, arsenite and arsenate can have profound effects on cellular differentiation, including potential apoptosis (Chen et al., 1996) .
The apparent human sensitivity to cancers induced by arsenic, combined with the lack of understanding about mechanisms of carcinogenic action, creates important public health concerns about arsenic and presents major challenges in risk assessment. The absence of animal models for arsenic carcinogenesis adds significantly to the uncertainties involved in defining its mechanisms of action. Furthermore, there is controversy on how exactly to extrapolate human exposure data from highly exposed, non-U.S. populations, in order to establish the risk from lower levels that are present in U.S. drinking water.
These concerns can be addressed, in part, by focusing on the role that metabolism plays in arsenic toxicity and carcinogenesis. In mammals, the biotransformation of arsenic is based on several generally accepted steps (Fig. 3) . For methylation to occur, arsenate (As 5ϩ ) species must be reduced to arsenite (As 3ϩ ), a process that occurs through reactions involving glutathione (GSH). Arsenite is sequentially methylated, first to form monomethylarsonic acid (MMA) and subsequently to form dimethylarsinic acid (DMA). Oxidative addition of methyl groups to arsenic occurs by, as yet, only partially characterized methyltransferase enzymes, with S-adenosyl-me- 
FIG. 3.
The biotransformation pathways for arsenic. Metabolism of inorganic arsenic species involves glutathione (GSH) as a cofactor. Methylation of arsenic is catalyzed by methyltransferases and requires the cofactor S-adenosyl-methionine (SAM) as the methyl donor. SAH, S-adenosyl-homocysteine. thionine (SAM) as the methyl-donating cofactor (Aposhian et al., 1997; Thompson, 1993) . The methylation of inorganic arsenic has been considered a detoxication mechanism, since arsenic-methylated compounds are less acutely toxic and less reactive with tissue macromolecules, and are excreted faster in urine than compounds of inorganic arsenic. On another level, arsenic is enigmatic, in that some evidence suggests that arsenic metabolites may contribute to the carcinogenicity or toxicity of the metalloid (Yamamoto et al., 1995) . An open question exists as to which arsenic species are, in fact, the ultimate carcinogens. The following presentations stemming from a recent symposium at the 1998 Annual Meeting of the Society of Toxicology address some of these critical concerns in arsenic carcinogenesis. These presentations were divided into three major areas: biotransformation of arsenic, molecular mechanisms of arsenic carcinogenesis, and the impact of arsenic dose-response relationships in humans on risk assessment. The purification and properties of the enzymes involved in the biotransformation of inorganic arsenic are of critical importance in defining mechanisms of arsenic toxicity (Aposhian, 1997) . Human liver arsenate reductase, the product of which is arsenite, requires an unknown heat-stable cofactor to be active. It does not appear to be any of the metal ions usually found as enzyme cofactors. The reduction of arsenate to arsenite produces the substrate for arsenite methyltransferase, which has been purified over 4000-fold from rabbit liver (Zakharyan et al., 1995) . Arsenite methyltransferase, which methylates inorganic arsenite to MMA, and MMA methyltransferase, which produces DMA, appear to be the same protein, with a molecular weight of ϳ60,000 Da and apparently made up of 2 monomers. Two isozymes of rabbit liver arsenite methyltransferase have been found and purified ϳ4000-fold.
Biodiversity of Inorganic
There is a striking biodiversity of liver arsenic methyltransferases. Marmoset (Vahter et al., 1982; Vahter and Marafante, 1985) , chimpanzee (Vahter et al., 1995) and guinea pigs do not excrete MMA or DMA and they are deficient in arsenic methytransferase Zakharyan et al., 1996) . Gorilla (unpublished), tamarin (Zakharyan et al., 1996) and the orangutan (unpublished) also are deficient in liver arsenic methyltransferases. Rhesus monkey (Zakharyan et al., 1996) , rabbit (Zakharyan et al., 1995) , mouse (Healy et al., 1998) , rat (Buchet and Lauwerys, 1988; Styblo et al., 1995) and hamster (Wildfang et al., 1998) have liver arsenic methyltransferases. Since a number of mammals are either deficient in, or lack, the arsenic methyltransferases, the question must be raised as to whether methylation is the primary detoxication pathway for inorganic arsenic. Perhaps protein binding of arsenic species is the initial detoxication mechanism for inorganic arsenic (Bogdan et al., 1994) . Diversity also exists in the arsenic methyltransferase activity of various tissues within the same species. For instance, in B6C3F1 mice, arsenite methyltransferase activity occurs in the following order: testis Ͼ kidney Ͼ lung ϭ liver (Healy et al., 1998) . Therefore, it is clear the liver is not the only organ which can methylate inorganic arsenite.
In addition to these enzyme studies dealing with the biotransformation of inorganic arsenic, we have begun studies of humans having different ethnic backgrounds who have been exposed to high levels of arsenic in their drinking water. Sodium 2,3-dimercapto-1-propane sulfonate (DMPS, Dimaval R ) is a water soluble, chelating agent that can be given by mouth or systemically and has been used to treat metal intoxication since the 1950Јs in the former Soviet Union and since 1978 in Germany (for reviews see Aposhian, 1983; Aposhian et al., 1995) . It can be used to approximate the body burden of mercury and arsenic. The protocol for the DMPS arsenic challenge test consists of an overnight fast followed by the administration of 300 mg DMPS po and collection of urine at prescheduled times thereafter . DMPS altered the levels of urinary arsenic in humans chronically exposed to arsenic in their drinking water . San Pedro de Atacama, a relatively isolated town in the Atacama desert in northeast Chile, was a study location. The drinking water has 593 g arsenic/l. The source of this arsenic is the runoff from high volcanic formations in the Andes. Toconao, the control town, was about 40 km away from San Pedro de Atacama in Chile. The drinking water here contains about 19 g As/l.
It was surprising that there was a marked increase in the amount of urinary MMA being excreted in the urine of both the San Pedro and Toconao groups after DMPS challange. There was approximately a 9-fold increase in urinary MMA during the 2-h period after DMPS administration as compared to the previous 2 h. Urinary inorganic arsenic was increased about 5-fold and DMA less than 2-fold. For the Toconao subjects, although the amounts of arsenic species per 2-h period were much less compared to San Pedro, the fold increases relative to the preceding time period were similar.
The most striking change found in our Chilean study was that the percentage of MMA in the total urine arsenic increased to an extent never seen in any previously reported study in humans or animals . The mean MMA% increased from 15% (San Pedro de Atacama) and 12% (Toconao) before DMPS administration to 42% for each group during the 0 -2-h period after DMPS. The usual percentage of MMA reported in human urine has had a range of 10 -20%. The increase in MMA% was accompanied by a substantial decrease in DMA%. Although DMPS administration resulted in significant changes in the percent of these various arsenic species excreted in the urine of both San Pedro de Atacama and Toconao subjects, the magnitude of the changes in relative percentage were essentially the same for both groups. With the increasing concerns about the carcinogenicity of DMA, DMPS may be of value in decreasing DMA concentrations in the body.
Our laboratory is continuing the study of arsenite methyltransferases by determining the amino acid sequence of the rabbit liver enzyme so that its gene can be isolated. Such information should allow nucleotide probes to be constructed that may be useful in screening large populations for the presence or absence of these enzymes that biotransform inorganic arsenic. In addition, we are analyzing urine from subjects in Inner Mongolia who drink water containing high levels of arsenic and for whom we have given DMPS. The comparison of this group with the native Chileans may give a more definitive answer to questions about genetic polymorphisms in arsenic metabolism. The results of such studies should help unravel many of the enzymes associated with the exposure of humans to inorganic arsenic. (Supported in part by the Superfund Basic Research Program NIEHS Grant ES-04940).
The Association of Arsenic-Induced Malignant Transformation with DNA Hypomethylation and Aberrant Gene Expression (Michael P. Waalkes and Chris Zhao)
Although there is clear evidence for carcinogenesis by arsenic in humans, animal evidence is considered equivocal. Thus the possibility exists that humans may be particularly sensitive to arsenic-induced cancers, and defining the mechanism is critical to defining the nature and extent of the human health hazard presented by environmental arsenic exposure. Typically, arsenic is negative in most in vitro mutagenesis assays, at least at concentrations that permit reasonable cell survival (Wang and Rossman, 1996) . In light of this, it is possible that epigenetic mechanisms will apply to arsenic carcinogenesis.
In many cells, inorganic arsenic undergoes enzymatic monoand di-methylation, consuming SAM in the process. The methylation of arsenic occurs through incompletely characterized methyltransferases that typically show high activity in the liver. The fact that SAM is an essential methyl donating cofactor for many methyltransferases, including DNA methyltransferase, suggests a possible role for DNA methylation in arsenic carcinogenesis. DNA methylation contributes to the control of the expression a variety of genes (Counts and Goodman, 1995a) , including potentially that of oncogenes, such as c-myc and other genes like the metallothionein (MT) gene. Generally, DNA hypomethylation enhances gene expression while hypermethylation suppresses it; the most common site of methylation is 5-methylcytosine.
We have tested the hypothesis that early events in arsenicinduced carcinogenesis result from aberrant gene expression subsequent to DNA hypomethylation, caused by continuous methyl depletion (Zhao et al., 1997) . Transformation was induced in a rat liver epithelial-cell line (TRL 1215) by chronic exposure to low levels of sodium arsenite (125, 250, or 500 nM). Transformation was dependent on both arsenic dose and exposure duration. Malignant transformation was confirmed after subcutaneous inoculation of cells into nude mice by the development of highly aggressive malignant tumors that showed a high rate of pulmonary metastasis. The rate of tumor formation after inoculation was directly related to the dose of arsenic in vitro.
Global methylation of DNA was measured in arsenic-transformed cells by Southern blot analysis using rat satellite I repeat fragment probe pCR-J00784 and restriction isochizomers that are methyl sensitive (HpaII) and methyl insensitive (MspI). The results showed that global DNA hypomethylation occurred concurrently with arsenic-induced transformation and in the presence of significantly reduced cellular SAM levels. The extent of arsenic-induced DNA hypomethylation was also a function of both dose and exposure duration, and remained constant even after the withdrawal of arsenic. In this regard, arsenic-transformed cells maintained in arsenic-free media still produced malignant tumors upon inoculation into nude mice, signifying that heritable changes had occurred. In fact, the rate of tumor formation after inoculation into nude mice was highly correlated with the extent of hypomethylation.
Consistent with hypomethylation as a mechanism of transformation, aberrant gene activations were also detected. In particular, activation of the c-myc oncogene was detected. Activation of c-myc often occurs during hepatocarcinogenesis and can induce transformation without mutation by simple overexpression (Leder et al., 1986) . Increased basal expression and hyperinducibility of the MT gene, a gene for which expression is clearly controlled by DNA methylation status (Compere and Palmiter, 1981) , was also detected in arsenictransformed cells. Acute arsenic or arsenic at non-transforming levels did not induce global DNA hypomethylation or activate c-myc. Enzymatic activity of DNA methyltransferase was reduced in arsenic-transformed cells, possibly due to feedback inhibition, while transcription of DNA methyltransferase gene was elevated, possibly as an attempt to compensate for reduced enzyme activity.
These results indicate that arsenic may act as a carcinogen by inducing DNA hypomethylation, which in turn causes aberrant gene expression, and constitute a tenable theory of mechanism in arsenic carcinogenesis.
Mechanisms of Arsenic Induced Cancer: A Role for
Hypermethylation (Marc J. Mass)
The effects of inorganic arsenic might be mediated as a result of interference with a common set of pathways that encompass DNA damage/repair, cell cycle, and/or differentiation. Such pathways include those controlled by a set of tumor suppressor genes, the perturbation of which results in a con-stellation of effects terminating in compromise of genomic stability. We have been testing the hypothesis that the carcinogenic effects of inorganic arsenic might be the result of interference with DNA methylation. Perhaps this happens through linkage between the arsenic (arsenite) detoxication pathway and the fact that altered DNA methylation can alter gene expression in a potentially heritable way. Both hypermethylation and hypomethylation have been implicated in alteration in genomic stability (Counts and Goodman, 1995b) .
In our studies reported at this symposium, human lung A549 cells were exposed to arsenite, arsenate, or DMA for approximately 2 weeks. Cytosine methylation in a portion of the promoter region of the p53 tumor suppressor gene, whose transcription is methylation-sensitive (Schroeder and Mass, 1997) , was assessed using an HpaII restriction/PCR-based assay, DNA sequencing using bisulfite was employed to visualize 5-methylcytosine (Frommer et al., 1992) , and SssI methylase assays were used for CpG methylation as a measure of genomic methylation. We observed that continuous exposure of A549 cells in culture to arsenite at 0.08 M to 2 M, and arsenate at 30 to 300 M, but not DMA (up to 2000 M), results in dose-responsive increases in cytosine methylation of approximately 7-fold in a portion of the p53 promoter (a 341-bp fragment) containing major transcription start sites. The HpaII/PCR assay suggests that hypermethylation exists only in a small population of cells, on the order of 10%. SssI methylase assays showed that arsenite can cause a small increase in global CpG methylation. Assays for the activity of cytosine methyltransferase (CMeTase) in A549 cells cultured in the presence of arsenite exhibited an increase in this activity over the 2-week culture period; using RT-PCR we confirmed that the mRNA for CMeTase was also elevated.
The mechanism for arsenic-induced hypermethylation is unknown. We have speculated that arsenic has the ability to alter DNA methylation (hypo-and hypermethylate) by several mechanisms (Mass, 1992; Mass and Wang, 1997) . Hypomethylation might result from arsenic draining methyl groups from the SAM pool upon its methylation by arsenic methytransferase (Mass, 1992; Zhao et al., 1997) . Hypermethylation is not as easily explained. A hypermethylated p53 promoter may somehow allow selection for cells that are resistant to arsenic toxicity. Another hypothesis is that arsenic (as arsenite or arsenate) might act as a differentially specific inhibitor of the numerous methyltransferases that engage the SAM pool as the methyl donor. Over 100 SAM-dependent methyltransferases are known. Because arsenite is a substrate for a methyltransferase(s), it is conceivable that sequence commonalities in methyltransferases cause them to recognize arsenite as an alternative substrate or cofactor. The activity of several other methytransferases (which have metal binding domains) might be affected by arsenic as a stimulator of activity, or as a pseudo-or suicide-substrate resulting in inhibition of these enzymes. Arsenic is a sulfhydryl-binding reagent and can inhibit active sites of enzymes with vicinal dithiols. It is known that selenocysteine methyltransferase is strongly inhibited by arsenite at micromolar concentrations (Hsieh and Ganther, 1977) . If a net inhibition of methyltransferase activities results from initial arsenic exposure, then a transient increase in SAM levels due to lack of utilization of SAM could conceivably drive functioning, arsenic-resistant methyltransferases at a higher level of product production. If CMeTase is significantly less resistant to arsenite inhibition, then it might be driven to over-methylate its substrate, resulting in DNA hypermethylation. Our preliminary studies using isolated crude CMeTase preparations have shown that CMeTase activity can be maintained at arsenite concentrations of 10 mM, and is consistent with the concept of methyltransferases with varying sensitivities to inhibition by arsenic.
Our present and future activities are directed toward determining the basis for the alterations in methylation of the p53 promoter. These are seen in response to arsenite exposure and determining whether cytosine methylation changes are present in promoter regions of other genes that may be important in arsenic carcinogenesis. We will be exploring the effect of arsenic exposure on DNA methylation patterns of genes where there is a well-established linkage between alterations of DNA methylation and expression.
Impact of Arsenic Metabolism on Human Populations: Metabolism of Arsenic and Sensitivity to Carcinogenesis in Humans (L. M. Del Razo, G. G. García-Vargas, A. Albores, and M. E. Cebrián)
A central issue in arsenic toxicology, concerning the relationship between toxicokinetic parameters and resulting health effects, is the role of arsenic metabolism in the overall mechanism of carcinogenesis. Acute studies on experimental animals and humans have provided evidence suggesting that the rate of inorganic arsenic methylation decreases with increasing dose level (Buchet et al., 1981) . Other factors influencing the metabolism of arsenic in humans include: (1) differences in nutritional status, since a lower methylation efficiency occurs with low intake of methionine and protein (Vahter, 1994) , and (2) polymorphic activities of the enzymes that catalyze arsenic methylation. However, the role of genotype in inter-individual variation in the arsenic methylation pathway has not been determined.
Chronic arsenic poisoning is endemic in Region Lagunera, México, and severe adverse effects attributed to arsenic exposure have been reported there . Pilot studies compared the urinary excretion pattern of arsenic species between exposed and control individuals from this area. The exposed individuals showed increases in the proportion of MMA, accompanied by decreases in the proportion of DMA excreted in urine, without significant changes in the proportion of inorganic arsenic excreted. This result suggests that chronic arsenic exposure primarily influenced the conversion of MMA to DMA . Since the intensity and duration of the toxic action is proportional to the concentration of the ultimate toxicant at the site of action and the length of time it remains there, alterations in the efficiency of arsenic biotransformation could have important implications for assessing the risk derived from exposure to this metalloid.
We have analyzed the relationships among alterations in the profile of urinary arsenic species, the magnitude of arsenic exposure, and the presence of cutaneous signs of chronic arsenicism. The profile of arsenic species in urine was studied in populations with high and low lifetime exposures to arsenic in drinking water (0.408 and 0.019 mg/L). We used the concentrations and proportions of inorganic arsenic, monomethylarsonic acid (MMA), dimethylarsinic acid (DMA), and the ratio DMA/MMA as indicators of methylation capacity. The association of the various forms of arsenic with exposure variables and with the presence of cutaneous signs of arsenicism were examined. We compared total arsenic in urine (TAsU) in 180 high-and 112 low-exposed individuals and found 0.76 and 0.05 mg/L, respectively. TAsU was linearly related to the estimated As intake (mgAs/kg/day) and to timeweighted individual exposure (TWIE) values. The high-levelexposure group had significantly higher concentrations and proportions of MMA, lower concentrations of DMA, and thus a lower DMA/MMA ratio. The individuals with cutaneous signs in the high-exposure group had higher MMA, lower DMA, and higher TWIE values than individuals from the same group without cutaneous signs. Arsenic-exposure variables, as well as age and sex, were important factors in explaining the altered profile of arsenic species in urine. These results indicate that the magnitude of the exposure is the single most important factor affecting arsenic methylation, and that high chronic arsenic exposure decreases the body's ability to methylate inorganic arsenic to MMA and DMA. The data also suggest that the presence of cutaneous signs of chronic arsenicism is related to a further impairment of arsenic metabolism leading to an accumulation of MMA. Possible explanations for impairments in the arsenic-methylation process include saturation or inhibition of arsenic methyltransferases and/or depletion of cofactors such as SAM and/or GSH. The increasing demands on the SAM pool, posed by arsenic methylation, could also affect the activities of enzymes requiring SAM, such as the DNA methyltransferases. The role played by these effects in the mechanism(s) of arsenic carcinogenesis should be investigated.
Impact of Inorganic Arsenic Metabolism on Human Populations: Dose-Response Relationships in ArsenicInduced Cancers (Tracey Slayton and Barbara D. Beck)
The shape of the dose-response relationship for arsenic carcinogenicity is a critical factor in accurately assessing arsenic cancer risks, particularly at low levels of exposure. Epidemiology studies, the source of much of our information on the toxicity of arsenic in humans, can provide only limited information about dose-response relationships at the low doses typically experienced by U.S. populations. Recent reviews of arsenic epidemiology studies found that the current EPA cancer slope factor (CSF) for arsenic is likely to over-predict skin cancer cases at relatively low levels of exposure (arsenic drinking water levels up to 400 g/L) (Guo and Valberg, 1997; Valberg et al., 1998) . Since EPA calculated the current CSF assuming a nearly linear dose-response relationship, these recent results suggest that the arsenic dose-response curve may be non-linear. One plausible biological explanation for nonlinearity is the fact that in most cases, arsenic indirectly induces genetic damage with a sublinear dose response (Rudel et al., 1996) . As another plausible explanation, we evaluated the role of arsenic metabolism and mechanisms for evidence of non-linearity in the low-dose region of the dose-response curve for arsenic carcinogenicity.
The question of whether methylation is the primary detoxication pathway for arsenic continues to be debated. As early as 1981, Buchet measured urinary concentrations of inorganic arsenic, MMA, and DMA in volunteers ingesting repeated doses of arsenic, and found reduced arsenic methylation with increasing doses, suggesting possible impairment of methylation at sufficiently high doses (Buchet et al., 1981) . We reviewed urinalysis results from more recent environmental studies to further evaluate the efficiency of arsenic methylation as a function of dose, and the relevance for human health effects.
We reviewed thirteen published studies that reported urinary concentrations of inorganic arsenic, MMA, and DMA (Del Razo et al., , 1995 Farmer and Johnson, 1990; Foa et al., 1984; Hopenhayn-Rich et al., 1995 Hseuh et al., 1995; Kalman et al., 1990; Smith et al., 1977; Vahter et al., 1996; Warner et al., 1994; Yamamura and Yamauchi, 1980; Yamauchi et al., 1989) . Seven of the studies considered residential exposures to arsenic in drinking water, 1 considered residential exposure to arsenic in soil, and 5 considered occupational exposure to airborne arsenic. For each study, we evaluated ratios of urinary inorganic arsenic, MMA, and DMA as functions of dose, calculating ratios when they were not provided by the study authors. As assumed by Del Razo et al. (1997) , we considered the ratio of MMA/inorganic arsenic to be an indicator of the first methylation step, DMA/MMA to be an indicator of the second methylation step, and DMA/inorganic arsenic to be an indicator of total methylation. We used total speciated urinary arsenic (the sum of inorganic arsenic, MMA, and DMA) as a surrogate measure of arsenic exposure.
Within the majority of the studies, the proportion of DMA and ratios of DMA/MMA and DMA/inorganic arsenic tended to be somewhat lower in populations with higher total urinary arsenic levels. The proportion of inorganic arsenic tended to increase with increasing dose. There was no dose-related trend in the proportion of MMA. These results suggest that methylation is somewhat impaired with increasing exposure.
To further evaluate arsenic methylation patterns, we ana-lyzed pooled data from 5 of the drinking water studies (Del Razo et al., 1995; Hopenhayn-Rich et al., 1993 Hseuh et al., 1995a; Warner et al., 1994) . These studies were determined to be most comparable, because they included populations of both men and women with chronic exposure to arsenic in drinking water. The ratios of DMA/MMA, MMA/inorganic arsenic, and DMA/inorganic arsenic were plotted as functions of total urinary arsenic for both the exposed and control groups from each of the 5 selected studies. We then fit a linear regression to each combined data set to determine whether there was a consistent relationship between methylation efficiency and arsenic exposure levels across studies. The results for DMA/inorganic arsenic ratios are shown in Figure 4 . While there was considerable variability across studies, as a general trend, DMA/inorganic arsenic and DMA/MMA ratios tended to decrease with increasing total urine arsenic concentrations. The percentage of inorganic arsenic tended to increase with increasing dose. These trends across studies are also consistent with the hypothesis that arsenic methylation is impaired with increasing exposure. It should be stressed, however, that these apparent dose-dependent changes in methylation efficiency are subtle; arsenic methylation does not appear to saturate completely at higher doses. Mann et al. (1996) came to a similar conclusion in developing a physiologically based pharmacokinetic (PB-PK) model for inorganic arsenic exposure in humans. At doses up to 15 g As/kg body weight, their model predicts a decrease in the proportion of DMA and an increase in the proportion of inorganic arsenic in urine (i.e., a decrease in methylation capacity) with increasing doses.
An outstanding question is the toxicological significance of moderate changes in methylation efficiency. Del Razo et al. (1997) recently measured arsenic metabolites in urine from a group of individuals from Region Lagunera, Mexico, with chronic exposure to arsenic in drinking water (average 415 g As/l). Based on a comparison of urinary arsenic methylation patterns among exposed individuals, those with cutaneous signs of chronic arsenicism had significantly lower DMA/ MMA ratios, and significantly higher proportions of MMA and MMA/inorganic arsenic ratios. One possible explanation for this finding is that higher doses of arsenic may alter metabolism and methylation rates, which may increase the dose at target tissues, which may in turn increase the development of adverse health effects.
This hypothesis that dose-dependent changes in metabolism affect the concentration at target tissues is further supported by the results of an acute mouse study (Hughes et al., 1994) . A significantly higher percentage of the dose was found in the bladder, kidney, liver, and lung of the mice administered 5000 g sodium arsenate per kg body weight (the highest dose group), compared to the lower dose groups. This increase in tissue binding was observed before changes in urinary arsenic metabolite ratios were seen. In contrast, there was no observed increase in tissue binding or urinary metabolites in a 4-week mouse study (Hughes and Thompson, 1996) ; however, the daily dose for the high exposure group was approximately 500 g/kg, about 10-times lower than the maximum dose tested in the acute study.
In addition to the magnitude of the arsenic dose, various other factors may influence arsenic methylation efficiency. For example, genetic polymorphism in the methyltransferases responsible for arsenic methylation is one proposed explanation for the atypical pattern of urinary arsenic metabolites observed in native Andean women . In rabbits, nutritional deficiencies have been shown to impair arsenic methylation, despite the presence of an excess in the total molar quantity of donor methyl compounds (Vahter and Marafante, 1987) .
Interpreting the health significance of dose-dependent alterations in arsenic methylation remains complicated by numerous unresolved issues. The observed changes in metabolite ratios are modest (albeit associated with clinical signs in one study), and it is unclear whether the first, second, or both methylation steps are impaired. Additional data are needed to fully understand the relevance of altered methylation patterns with respect to dose at target tissue, the mechanisms of arsenic carcinogenesis, and the rate-limiting step in arsenic toxicity. The fact that susceptibility is not increased in animal species unable to methylate arsenic raises additional questions about the significance of arsenic methylation, although it may be that these species have other means, e.g. protein binding, for reducing arsenic toxicity. The basis for variability in arsenic metabolism between both populations and individuals remains unclear. Despite these uncertainties, overall, the available data show that arsenic methylation is somewhat impaired with increasing arsenic dose, and this finding is consistent with a non-linear dose-response relationship for arsenic carcinogenesis. 
CONCLUSIONS
This symposium review covered three major areas involving arsenic metabolism that are critical to our understanding of the processes involved in arsenic carcinogenesis. These included species biodiversity in arsenic metabolism, the role of arsenic metabolism in the molecular mechanisms of carcinogenesis, and the impact of arsenic metabolism on human risk assessment. Although important uncertainties remain, significant progress towards addressing some of the difficult questions was made. In the biodiversity of the biotransformation of arsenic, it is clear that species vary widely from one another, and from humans, in their ability to methylate arsenic. There are also indications that phenotypic heterogeneity for arsenic metabolism may exist in human populations. The question as to whether methylation of arsenic is a detoxication pathway for the chronic toxic effects of arsenic, such as cancer, remains open. The fact that some mammals do not methylate arsenic suggests that methylation is not the only, or even the primary, detoxication pathway. Isolation and characterization of the enzymes involved in arsenic biotransformation and defining the expression of the corresponding genes will be very important steps in answering these questions. The remarkable species diversity in arsenic methyltransferases may contribute well to our understanding of the species differences in sensitivity to arsenic-induced toxicity or cancer.
An important implication concerning the role of arsenic metabolism in the mechanisms of arsenic carcinogenesis is the competition or interference of arsenic with normal metabolic pathways. The arsenic metabolic pathway consumes cellular methyl groups that may modify the activity of a variety of methyltransferases. Alternatively, direct stimulation or inhibition of methyltransferases is a distinct possibility. The alteration in cellular methylation reactions could have effects that are critical to gene expression. Arsenic may thus interfere with methylation of DNA that in turn could cause aberrant expression of genes important in the control of cell proliferation, such as oncogenes or tumor suppressor genes. Other issues that may come into play, which were not addressed in the symposium, include the role of arsenic in generation of reactive oxygen species and the effects of arsenic on DNA repair or modification of cellular proliferation.
Assessing the role of arsenic metabolism in defining the sensitivity of human populations to environmental arsenic exposure is, of course, a most pressing issue. In this regard, urinary arsenic metabolites may be valuable biomarkers for assessing human susceptibility to arsenic carcinogenesis. Unique arsenic metabolism may explain the apparent nonlinear, threshold response for arsenic carcinogenesis in humans. The dose-dependant changes in the ability to methylate arsenic may modify the toxic response at high doses in a fashion that would not apply to lower doses.
Overall, these presentations have demonstrated the difficulties in accurately assessing the risk of carcinogenesis from arsenic exposure. Among a variety of important challenges, the absence of a validated experimental animal model to study carcinogenic mechanisms remains a serious hindrance. The species and tissue biodiversity in arsenic metabolism create important questions as to models of choice and of phenotypic heterogeneity in human populations that may determine sensitivity. An apparent non-linear dose response, which may be dictated by dose-dependent changes in the ability to methylate the metalloid, also creates challenges in assigning low-dose risk based on high-dose metabolism. Most of the modes of action identified for arsenic carcinogenesis support a non-linear dose-response at low-level exposures, i.e., the slope decreases as the dose decreases (Fig. 5) ; however, this has yet to be definitively established. Future research directions should include identifying an appropriate animal model for studying arsenic carcinogenesis, analyzing the genetic constitution of arsenic-induced tumors, assessing the potential contribution of arsenic metabolites to carcinogenesis and the possible cocarcinogenic effects of arsenic, and studying the contribution of dietary depletion of choline and methionine in susceptibility to arsenic carcinogenesis. Undertaking such studies will support efforts in elucidating mechanisms of action and defining the dose-response relationship for this very important human carcinogen.
